Management of sexually transmitted syndromes is facilitated by having antimicrobial agents active against all of the major genital pathogens. Currently marketed macrolides are useful for treatment of Chlamydia trachomatis infection, but there is laboratory (10) and clinical evidence that erythromycins are not always effective (1) and macrolides in higher doses are often poorly tolerated (3). Macrolides are not advocated for use in the treatment of infections due to Neisseria gonorrhoeae (6) . Development of newer macrolides with increased in vitro activity against both of these organisms or better tolerance or activity in vivo could be a useful advance. Like older cephalosporins, newer ones are not anticipated to be active against C. trachomatis, but newer cephalosporins have high activity against N. gonorrhoeae (4) , and ceftriaxone has assumed major importance in the management of gonococcal infections (6) . Oral cephalosporins with high activity against N. gonorrhoeae in vivo would be highly useful because they would circumvent the need for an injection and related equipment. In this study, the in vitro activity of the newer macrolides, A-56268 and roxithromycin (RU 28965) , and the cephalosporins, Ro 15-8074 and Ro 19-5247 (T2525), were evaluated for in vitro activity against either or both N. gonorrhoeae and C.
trachomatis.
Most non-beta-lactamase-producing isolates of N. gonorrhoeae were obtained from men Oxidase-positive colonies showing typical colonial morphology and containing gram-negative diplococci were identified as N. gonorrhoeae by fluorescent-antibody staining or sugar fermentation or both. Ten or more colonies were subcultured to chocolate agar, and a modification of the iodometric paper strip was used to screen for beta-lactamase activity (9) . The presence of beta-lactamase activity in isolates positive by the iodometric test was confirmed with chromogenic cephalosporin (nitrocefin) (Glaxo Pharmaceuticals, Ltd., Greenford, England) (7). Isolates were stored at -70°C in glycerol citrate. The study included 235 isolates for which the MICs of penicillin were <1 ,ug/ml, 44 chromosomally mediated resistant N. gonorrhoeae isolates that were not beta-lactamase producing and for which the MICs of penicillin were 1 to 4 ,ug/ml, and 131 beta-lactamaseproducing strains of N. gonorrhoeae. Isolates were tested by standard agar dilution techniques (7) In vitro susceptibility testing was performed on 10 clinical isolates of C. trachomatis by our previous methodology (2) . The MICs and MBCs were determined for each strain in 1 h, the antimicrobial agents were then added, and the cultures were incubated. In experiments to determine the MICs, the concentrations of antimicrobial agents required to prevent development of C. trachomatis inclusions, the vials were incubated for 72 h and then stained with iodine. For experiments to determine the MBCs, the concentrations of antimicrobial agents that resulted in no inclusion formation when infected monolayers exposed to antimicrobials agents were passed to new monolayers without antimicrobial agents, the monolayers were incubated for 48 h, rinsed twice with 0.04 M sucrose phosphate, and then overlaid with 0.04 M sucrose phosphate and frozen at -70°C. They were then thawed and inoculated onto fresh cells, incubated for 72 h, and stained with iodine. The MIC and MBC are the concentrations at which no inclusions were seen in triplicate vials.
The range of MICs and the MICs for 50 and 90% of N. gonorrhoeae isolates are indicated by category (those showing beta-lactamase production, chromosomally mediated resistance, and penicillin MICs of <1.0 ig/ml) in Table 1 . Results with penicillin and erythromycin were as expected (5 (11) .
Results for the C. trachomatis MICs are shown in Table 2 . MBC results were almost identical and are not shown. Results with tetracycline and doxycycline were similar to those produced before (2) . Erythromycin appeared less active than it did in our initial work (2), but results were similar to our more recent results (unpublished). Activity of roxithromycin was similar to that of erythromycin. In contrast, A-56268 was almost identical to tetracycline in activity. As anticipated, Ro 15-8074/003 was not active against C. trachomatis in vitro.
These studies indicate that A-56268, with in vitro activity similar to that of tetracycline, has considerable promise as an antimicrobial agent for use in treatment of chlamydial infections. In vitro data suggest that it would not be an improvement over erythromycin for gonocococcal infections. Roxithromycin had activity similar to that of erythromycin against C. trachomatis and could be effective for nongonococcal urethritis and nongonococcal cervicitis. The studies of others indicate that it also has activity against N. gonorrhoeae similar to erythromycin activity (8) . The 
